Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by James Rhoads.
Journal of Clinical Microbiology | 2007
Vincent Thibault; Christian Pichoud; Carolyn Mullen; James Rhoads; Jane B. Smith; Alain Bitbol; Sven Thamm; Fabien Zoulim
ABSTRACT Sensitive and accurate quantification of hepatitis B virus (HBV) DNA is necessary for monitoring patients with chronic hepatitis receiving antiviral therapy in order to determine treatment response and to adapt therapy in case of inadequate virologic control. The development of quantitative PCR assays has been crucial in meeting these needs. The objective of this study was to compare the performance of a new real-time PCR assay (Abbott RealTime) for HBV DNA with that of three other commercial assays for the detection of HBV DNA. These were the Versant 3.0 branched-chain DNA assay, the Cobas Amplicor HBV Monitor test, and the Cobas AmpliPrep-Cobas TaqMan hepatitis B virus assay (CAP-CTM). HBV DNA was measured in blood samples taken from two cohorts of patients with chronic hepatitis. HBV DNA levels measured with the Abbott RealTime assay were highly correlated with those measured with the other three tests over their respective dynamic ranges (r, 0.88 to 0.96). The sensitivity (detection limit, 10 IU/ml) and dynamic range of the Abbott RealTime assay (101 to 109 IU/ml) was superior to that of the Versant assay. The RealTime assay recognized both HBV strains belonging to genotypes A to G and those bearing polymerase gene mutations equivalently. In conclusion, this study demonstrates the utility of the Abbott RealTime assay for monitoring HBV DNA levels in patients with chronic hepatitis B. Its sensitivity and wide dynamic range should allow optimal monitoring of antiviral therapy and timely treatment adaptation.
Journal of Clinical Microbiology | 2013
Gavin Cloherty; James Rhoads; Thomas P. Young; Neil T. Parkin; Vera Holzmayer; Lilly Yuen; Carolyn Mullen
ABSTRACT The Abbott RealTime HBV assay targets the N-terminal region of the S gene. Here we analyzed the sequence variability of the assay target region from >2,100 clinical specimens. Thermodynamic modeling of the percentage of bound primer/probe at the assay annealing temperature was performed to assess the potential effect of sequence variability.
Journal of Clinical Microbiology | 2014
Gavin Cloherty; Neil T. Parkin; James Rhoads; Claudia Esping; Corklin Steinhart; George Schneider; Lily Yuen; John Hackett
ABSTRACT The Abbott RealTime (RT) HCV assay targets the 5′ untranslated region (UTR) of the HCV genome. Here, we analyzed the sequence variability of the assay target regions from 1,092 specimens. Thermodynamic modeling of the percentage of primers/probes bound at the assay annealing temperature was performed to assess the potential effect of sequence variability. An analysis of this large data set revealed that the primer and probe binding sites of the RealTime HCV viral load assay are highly conserved and that naturally occurring sequence polymorphisms are not expected to discernibly impact assay performance.
Archive | 2003
Carolyn Mullen; James Rhoads
Archive | 2016
Jeffrey D. Wuitschick; Kevin S. Nelson; Shihai Huang; Rupinder Kular; Carolyn Mullen; James Rhoads
Archive | 2014
T. Parkin; Vera Holzmayer; Lilly Yuen; Carolyn Mullen; Gavin Cloherty; James Rhoads; Thomas P. Young
Archive | 2012
Heather Alexander; James Rhoads; Edward Pabich; Kathleen S. Riesing; Carolyn Mullen
Archive | 2003
Carolyn Mullen; James Rhoads
Archive | 2003
Carolyn Mullen; James Rhoads
Archive | 2003
Carolyn Mullen; James Rhoads